Nevenibart Reduces Hereditary Angioedema Burden in Small Study’s Interim Analysis
HCPLive
FEBRUARY 16, 2025
At 6 months, baseline monthly rates of 0.45 for mild, 1.54 for moderate, and 0.14 for severe attacks were reduced to 0.10, 0.08, and 0.00, respectively.
Let's personalize your content